Keros Therapeutics, Inc. $KROS Position Boosted by Quadrature Capital Ltd

Quadrature Capital Ltd lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 62.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 47,000 shares of the company’s stock after acquiring an additional 18,129 shares during the quarter. Quadrature Capital Ltd’s holdings in Keros Therapeutics were worth $627,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KROS. Russell Investments Group Ltd. grew its position in Keros Therapeutics by 648.0% in the second quarter. Russell Investments Group Ltd. now owns 61,743 shares of the company’s stock worth $824,000 after buying an additional 53,489 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Keros Therapeutics by 12.5% during the 2nd quarter. XTX Topco Ltd now owns 54,145 shares of the company’s stock valued at $723,000 after acquiring an additional 6,024 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Keros Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after acquiring an additional 7,146 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Keros Therapeutics by 245.5% in the 2nd quarter. Franklin Resources Inc. now owns 132,301 shares of the company’s stock worth $1,766,000 after acquiring an additional 94,006 shares during the last quarter. Finally, Creative Planning grew its holdings in shares of Keros Therapeutics by 40.2% in the 2nd quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Trading Down 1.7%

NASDAQ:KROS opened at $17.18 on Tuesday. The business’s fifty day moving average price is $16.01 and its 200 day moving average price is $14.99. The firm has a market capitalization of $523.47 million, a price-to-earnings ratio of 11.16, a PEG ratio of 0.39 and a beta of 0.89. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.93. The company had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The business’s revenue for the quarter was up 3585.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.41) EPS. Equities analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. 22.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

KROS has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, November 24th. HC Wainwright cut their price objective on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Wedbush raised their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, Zacks Research raised shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Keros Therapeutics has an average rating of “Hold” and a consensus price target of $30.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.